Acceleron To Be Next M&A Target With Rumored $11bn Deal

BMS Seen As Most Likely Suitor

 
• By Andrew McConaghie
  
Acceleron
Bristol Myers Squibb is seen as the most likely acquirers, given its existing shareholding in Acceleron, and their co-marketing of Reblozyl. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

More from Scrip